Bristol-Myers blockbuster Opdivo fails to meet goal of brain tumour study

The drug, Opdivo, when used along with the current standard of care for glioblastoma multiforme, did not prevent cancer from spreading when compared with the standard of care alone, Bristol-Myers said.

U.S: Bristol-Myers Squibb Co said on Thursday its blockbuster cancer immunotherapy, Opdivo, failed to meet the main goal of a late-stage trial, testing it in patients with a type of tumour that affects the brain or spine.

The drug, when used along with the current standard of care for glioblastoma multiforme, did not prevent cancer from spreading when compared with the standard of care alone, Bristol-Myers said.

Read Also: Bristol-Myers posts strong second quarter as Eliquis, Orencia sales propel

Glioblastoma multiforme is the most aggressive type of primary malignant tumour of the central nervous system and the standard of care can include radiation and chemotherapy.

Read Also: Bristol-Myers to sell blockbuster Otezla for its $74 billion merger with Celgene